POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that its Digital Advisory Board, an esteemed group of digital thought-leaders both in and outside of healthcare, is participating in the eleventh annual ePharma Summit, a conference showcasing healthcare industry experts’ views on the evolution of digital marketing and how to reach consumers and physicians through social and digital media. A POZEN-sponsored panel discussion titled, “Transforming the Pharma Industry – Breakthrough Perspectives from Digital Leaders,” will be held on Tuesday, February 7, 2012 from 10:50 – 11:25 a.m. at the Sheraton New York Hotel & Towers.
“POZEN and its Digital Advisory Board are excited to be among the distinguished attendees speaking at this prominent digital marketing event,” said Liz Cermak, Executive Vice President and Chief Commercial Officer, POZEN Inc., and moderator of the discussion. “Comprised of some of the most influential voices and thought-leaders in the digital and social media space, our board will share their diverse perspectives and experiences and offer valuable insight into how pharmaceutical companies can leverage new digital strategies to more effectively engage physician and patient audiences.”
During the session, the Digital Advisory Board members will share their experiences, offering their perspectives on how to evolve traditional pharmaceutical marketing to best meet the needs of target audiences. The Digital Advisory Board has been working alongside POZEN as it prepares for the launch and marketing of its lead compound PA32540, which is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. They have helped POZEN design the actual Launch Plan for the brand.
About the Digital Advisory BoardPOZEN, a progressive, specialty pharmaceutical company, formed the Digital Advisory Board to help advance the Company’s vision of creating a new pharma commercial model.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV